TAP Uprima Erectile Dysfunction NDA Refiling Slated For 4Q, Abbott Says

15 Apr 2002

• By The Pink Sheet

TAP will refile an NDA for the erectile dysfunction disorder drugUprima in the fourth quarter, Abbott Pharmaceuticals President Jeff Leiden, MD/PhD, told analysts on a first quarter conference call April 9

TAP Uprima Erectile Dysfunction NDA Refiling Slated For 4Q, Abbott Says

More from Archive

More from Pink Sheet